InvestorsHub Logo
Followers 22
Posts 3636
Boards Moderated 0
Alias Born 07/20/2006

Re: None

Thursday, 01/04/2024 5:40:25 PM

Thursday, January 04, 2024 5:40:25 PM

Post# of 167
Collegium Pharmaceutical (NASDAQ:COLL - had its price target increased by investment analysts at Truist Financial from $31.00 to $37.00 in a report issued on Thursday, Benzinga reports. The brokerage presently has a "buy" rating on the specialty pharmaceutical company's stock. Truist Financial's price target indicates a potential upside of 16.68% from the stock's previous close.

https://www.marketbeat.com/instant-alerts/nasdaq-coll-boost-price-target-2024-01-04/

Jefferies Analyst Downgrades Collegium Pharmaceutical to Hold with Increased Price Target

On January 4, 2024, Jefferies analyst Glen Santangelo made a noteworthy adjustment to his assessment of Collegium Pharmaceutical (NASDAQ: COLL). Santangelo downgraded the stock from Buy to Hold, while simultaneously increasing the price target from $30 to $37.

https://beststocks.com/jefferies-analyst-downgrades-collegium-pharma/
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent COLL News